Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21114044 | 0.86 | KDM4E (0.40) | PDK2BACE1BACE2P2RY1KCNH2 | |
| SCHEMBL21114080 | 0.82 | PDK2 (0.40) | PDK2L3MBTL1P2RY1KCNH2TRPV4 | |
| SCHEMBL21163142 | 0.82 | PDK2 (0.42) | PDK2BACE1BACE2DDB1CRBN | |
| SCHEMBL21163146 | 0.80 | PDK2 (0.46) | PDK2BACE1BACE2USP30 | |
| SCHEMBL21163913 | 0.79 | PDK2 (0.32) | PDK2 | |
| SCHEMBL21114117 | 0.78 | PDK2 (0.45) | PDK2BACE1BACE2USP30 | |
| SCHEMBL21163145 | 0.77 | PDK2 (0.45) | PDK2BACE1BACE2USP30 | |
| SCHEMBL21114178 | 0.77 | PDK2 (0.44) | PDK2L3MBTL1BACE1BACE2USP30 | |
| SCHEMBL21113990 | 0.77 | PDK2 (0.44) | PDK2L3MBTL1BACE1BACE2USP30 | |
| SCHEMBL21163140 | 0.76 | PDK2 (0.51) | PDK2BACE1BACE2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, SERPINB1 | PDK2 3088/4885L3MBTL1 4479/4885BACE1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.